The latest announcement is out from Virpax Pharmaceuticals ( (VRPX) ).
Virpax Pharmaceuticals has announced a $5 million public offering of common stock and pre-funded warrants, set at $0.50 per share, to support its innovative drug delivery systems targeting pain management. The funds will aid in the development of Probudur, an injectable local anesthetic technology, and other corporate purposes. Spartan Capital Securities is managing the offering, which is expected to close on November 14, 2024.
See more insights into VRPX stock on TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Tesla Stock
- ‘Breath of Fresh Air,’ Says Daniel Ives About Rivian Stock
- ‘It’s Not Too Late to Load Up,’ Says Analyst About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
